INMED PHARMACEUTICALS INC. Net Income (Loss) Attributable to Noncontrolling Interest
INMED PHARMACEUTICALS INC. (INM) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$2.10 million for the 3-month period ending 2022-12-31, per its 10-Q filed 2023-02-17.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2023-02-17
- INMED PHARMACEUTICALS INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$2.10M.
- INMED PHARMACEUTICALS INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$4.28M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month |
|---|---|---|
| 2022-12-31 | -$2.10M 10-Q · filed 2023-02-17 | -$5.61M 10-Q · filed 2023-02-17 |
| 2021-12-31 | -$4.28M 10-Q · filed 2023-02-17 | -$7.25M 10-Q · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |